Neuralink

Type: Company (Brain-Computer Interface)

Neuralink is the most visible and well-funded player in invasive brain-computer interfaces. The company's N1 ("Telepathy") implant — a coin-sized intracortical device (reported variously as 1,024 electrodes / 64–128 threads) inserted into the cortex by a custom surgical robot in ~1.5 seconds — enables thought-controlled computing for patients with paralysis.

The PRIME (Precise Robotically Implanted Brain-Computer Interface) study has scaled from first-in-human to at least 24 patients implanted by May 2026 (up from ~12 in Sept 2025), demonstrating cursor control, typing, and gaming. The FDA granted breakthrough device designation, and the program has expanded internationally — CAN-PRIME (Canada, Nov 2024), GB-PRIME (UK, July 2025), and UAE-PRIME (Cleveland Clinic Abu Dhabi).

As of 2026 Neuralink is no longer a single-application cursor demo; it runs three distinct clinical programs:

• CONVOY — a PRIME extension testing robotic-arm control. In Oct 2025 ALS participant Nick Wray drank from a cup, microwaved food, opened a refrigerator, and set records on stroke-rehab dexterity tests (39 cylinders in 5 minutes).
• VOICE — speech restoration targeting the speech motor cortex (2 patients; FDA Breakthrough Device Designation; trial started Oct 3 2025, est. completion Oct 2028).
• Blindsight — visual-cortex stimulation to create perception in the completely blind, including those born blind (FDA Breakthrough Sept 2024; first trials slated for 2026 with Cleveland Clinic Abu Dhabi; demo video April 1 2026).

Neuralink's approach is maximally invasive (intracortical array requiring craniotomy) but achieves the highest per-channel signal quality of any commercial BCI. A second-generation device with a revised electrode design (addressing thread retraction) is in development, alongside plans for high-volume production and fully automated surgery. The company raised $650M in 2025 (~$9B valuation); realistic commercial-approval timelines extend to ~2028–2030.

Its long-term vision extends beyond medical restoration to neural augmentation — speculative and ethically fraught, but the medical-restoration pathway provides the commercial and regulatory entry point.

Key Contributions

• PRIME study: ≥24 patients with thought-controlled computing by May 2026 (Neuralink VOICE/scale)
• CONVOY robotic-arm control — real-world object manipulation by an ALS participant (Neuralink VOICE/scale)
• VOICE speech-restoration trial — FDA Breakthrough Device Designation (Neuralink VOICE/scale)
• Blindsight visual-cortex vision-restoration program — FDA Breakthrough (2024), first trials 2026 (Neuralink VOICE/scale)
• International expansion: CAN-PRIME / GB-PRIME / UAE-PRIME (Neuralink VOICE/scale)
• $650M raise (~$9B valuation); second-gen device + automated high-volume surgery planned (Neuralink VOICE/scale)
• Intracortical array with robotic surgical insertion (~1.5 s) (Neuralink PRIME)

Mentioned In

• Invasive vs. Non-Invasive BCI — Primary example of invasive BCI
• Neuroprosthetics — Motor function restoration clinical leader
• Neural Signal Decoding — High-bandwidth signal source for decoding
• Invasive BCI Devices — PRIME study clinical detail
• BCI Clinical Applications — Motor paralysis application

Related Entities

• Synchron — Minimally invasive (endovascular) competitor
• Paradromics — High-bandwidth intracortical competitor (Connexus, speech-first)
• Stanford Neural Prosthetics Lab — Academic research on similar intracortical approaches

Changelog

• 2026-04-14 — Created from PRIME expansion source (~20 patients, UK/UAE)
• 2026-06-24 — Major update: ≥24 patients by May 2026; added CONVOY (robotic arm), VOICE (speech, FDA Breakthrough), and Blindsight (vision) programs; CAN-/GB-/UAE-PRIME expansion; $650M raise / ~$9B valuation; second-gen device + automated surgery; linked Paradromics as third invasive-race competitor